ISIN | LU2814038266 |
---|---|
Valor Number | 134925902 |
Bloomberg Global ID | |
Fund Name | DNB Fund-Biotechnology Retail A EUR |
Fund Provider |
DNB Asset Management AS
Stockholm, Sweden Phone: +46 8 473 41 00 Web: www.cim.se |
Fund Provider | DNB Asset Management AS |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | |
Asset Class | Other Funds |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The Sub-Fund seeks to invest mainly in equities of companies operating in or associated with the biotechnology, diagnostics, pharmaceuticals, biomedicine, gene therapy and other health care related industries, with the aim to achieve a positive relative return over the long- term. Geographically the Sub-Fund has full flexibility. |
Peculiarities |
Current Price * | 94.76 EUR | 31.03.2025 |
---|---|---|
Previous Price * | 98.17 EUR | 28.03.2025 |
52 Week High * | 113.78 EUR | 11.11.2024 |
52 Week Low * | 94.76 EUR | 31.03.2025 |
NAV * | 94.76 EUR | 31.03.2025 |
Issue Price * | 94.76 EUR | 31.03.2025 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 5,521,847 | |
Unit/Share Assets *** | 2,182,233 | |
Trading Information SIX |
YTD Performance | -11.36% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
---|---|---|
YTD Performance (in CHF) | -9.77% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
1 month | -13.15% |
28.02.2025 - 31.03.2025
28.02.2025 31.03.2025 |
3 months | -11.36% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
6 months | -9.54% |
30.09.2024 - 31.03.2025
30.09.2024 31.03.2025 |
1 year | -11.59% |
19.07.2024 - 31.03.2025
19.07.2024 31.03.2025 |
2 years | - | - |
3 years | - | - |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Biomarin Pharmaceutical Inc | 6.81% | |
---|---|---|
argenx SE | 5.87% | |
Vertex Pharmaceuticals Inc | 4.80% | |
Amgen Inc | 4.10% | |
Neurocrine Biosciences Inc | 3.86% | |
Xenon Pharmaceuticals Inc | 3.49% | |
Alnylam Pharmaceuticals Inc | 3.41% | |
Regeneron Pharmaceuticals Inc | 3.19% | |
Axsome Therapeutics Inc | 3.12% | |
Exact Sciences Corp | 2.98% | |
Last data update | 28.02.2025 |
TER *** | 1.56% |
---|---|
TER date *** | 30.06.2024 |
Performance Fee *** | 10.00% |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.64% |
SRRI ***
|
|
SRRI date *** | 28.02.2025 |